MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$3,537K
Free Cash flow
-$3,073K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Grant income
Grant receivables
Others
Negative Cash Flow Breakdown
Clinical programs
General and administrative expen...
R&d personnel costs
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Grant income
3,518
3,979
9,999
13,407
Clinical programs
2,857
3,381
8,647
16,486
R&d personnel costs
1,758
1,594
1,522
6,221
Preclinical programs
63
619
184
262
Manufacturing
246
337
642
1,901
Other research and development expenses
41
51
8
222
General and administrative expenses (excluding equity-based compensation)
-
-
2,310
2,387
General and administrative expenses
2,454
2,505
-
-
Equity-based compensation
319
330
358
1,729
Other segment items
-288
-268
-329
-577
Net loss
-3,932
-4,570
-3,343
-4,930
Depreciation and amortization
10
11
14
22
Equity-based compensation
319
330
358
522
Amortization of right-of-use assets
45
57
47
46
Gain on lease modification
21
-
-
-
Loss on disposal of property and equipment
0
-5
-41
-
Grant receivables
-706
-6,266
8,023
-4,385
Prepaid expenses and other assets
-346
-136
-473
-47
Accounts payable and accrued expenses
-1,038
-7,570
8,414
-5,443
Deferred grant income and other liabilities
557
-147
-1,369
-246
Operating lease liabilities
-45
-60
-49
-47
Net cash used in operating activities
-3,053
-5,542
-3,437
-5,651
Proceeds from sale of property and equipment
-
-
9
-
Payments for property and equipment
20
-
-
-
Net cash used in investing activities
-20
-
9
-
Proceeds from issuance of common stock-Registered Direct Offering
-
-
-50
27,940
Proceeds from issuance of common stock under the atm sales agreements, net of commissions and allocated fees
6,737
-
800
5,989
Proceeds from the exercise of common stock options
0
44
6
65
Payment of employee withholding taxes on vested restricted stock units
11
164
77
36
Payments on loan payable
116
113
74
41
Net cash provided by financing activities
6,610
-233
605
33,917
Net decrease in cash, cash equivalents and restricted cash equivalents
3,537
-5,775
-2,823
28,266
Cash, cash equivalents, and restricted cash equivalents - beginning of period
31,225
37,000
39,823
25,009
Cash, cash equivalents, and restricted cash equivalents - end of period
34,762
31,225
37,000
39,823
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock under the...
$6,737K
(188.28%↑ Y/Y)
Net cash provided by
financing activities
$6,610K
(222.75%↑ Y/Y)
Canceled cashflow
$127K
Net decrease in
cash, cash...
$3,537K
(126.29%↑ Y/Y)
Canceled cashflow
$3,073K
Payments on loan payable
$116K
(-51.26%↓ Y/Y)
Payment of employee
withholding taxes on vested...
$11K
(-78.43%↓ Y/Y)
Grant receivables
-$706K
(-119.62%↓ Y/Y)
Deferred grant income and
other liabilities
$557K
(-39.19%↓ Y/Y)
Prepaid expenses and
other assets
-$346K
(47.01%↑ Y/Y)
Equity-based compensation
$319K
(-73.57%↓ Y/Y)
Amortization of right-of-use
assets
$45K
(-54.55%↓ Y/Y)
Depreciation and
amortization
$10K
(42.86%↑ Y/Y)
Net cash used in
operating activities
-$3,053K
(80.30%↑ Y/Y)
Net cash used in
investing activities
-$20K
Canceled cashflow
$1,983K
Grant income
$3,518K
(-71.15%↓ Y/Y)
Other segment items
-$288K
(17.00%↑ Y/Y)
Net loss
-$3,932K
(74.16%↑ Y/Y)
Payments for property and
equipment
$20K
Canceled cashflow
$3,806K
Accounts payable and
accrued expenses
-$1,038K
(-292.58%↓ Y/Y)
Operating lease
liabilities
-$45K
(58.33%↑ Y/Y)
Gain on lease
modification
$21K
Clinical programs
$2,857K
(-81.02%↓ Y/Y)
General and
administrative expenses
$2,454K
R&d personnel costs
$1,758K
(-64.65%↓ Y/Y)
Equity-based compensation
$319K
(-73.57%↓ Y/Y)
Manufacturing
$246K
(-78.61%↓ Y/Y)
Preclinical programs
$63K
(-72.00%↓ Y/Y)
Other research and
development expenses
$41K
(-81.94%↓ Y/Y)
Buy us a coffee
COGNITION THERAPEUTICS INC (CGTX)
COGNITION THERAPEUTICS INC (CGTX)